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patients with coronary artery bypass surgeryDear Editor,
We read the article “Plasma B-type natriuretic peptide in
predicting outcomes of elective coronary artery bypass
surgery” by Chen et al with interest [1]. The authors
investigated whether B-type natriuretic peptide (BNP) and
N-terminal proBNP (NT-proBNP) are correlated with
postoperative complications and outcomes after adjusting
for risk factors. They concluded that studies using BNP
and NT-proBNP levels for predicting intensive care unit
stay and hospitalization in patients who have undergone
coronary artery bypass graft must adjust risk factors to
present a more appropriate estimation of its clinical
outcome.
BNP is a cardiac neurohormone secreted by the ventri-
cles in response to end-diastolic pressure, related to vol-
ume load. Although most widely used as a marker of systolic
or diastolic dysfunction, elevated BNP level has been re-
ported in many conditions [2]. Therefore, it is important to
determine diastolic and systolic functions by echocardiog-
raphy. Performing echocardiography is also important for
measurement of pulmonary artery pressure. Pulmonary
arterial hypertension is commonly associated with rheu-
matic diseases and an elevated BNP level may be a result of
the increase in pulmonary pressure [3]. Natriuretic peptides
are secreted in response to a nonspecific pressure load of
any cardiac chamber, which is not only seen in cases of
heart failure, but also in cases of systemic hypertension,
atrial fibrillation, valvular disease, and even in some non-
cardiovascular conditions such as renal failure. One of the
prominent diseases with elevated BNP level is diseases of
the respiratory system such as chronic obstructive pulmo-
nary disease, pulmonary embolism, interstitial lung disease
in which BNP level is elevated in response to pressure on
the right side of the heart [4]. By contrast, high levels of
BNP can be seen in many cases, resulting in increased1607-551X/$36 Copyright ª 2013, Kaohsiung Medical University. Publish
http://dx.doi.org/10.1016/j.kjms.2013.09.006cardiac output and cardiac stress such as sepsis and hy-
perthyroidism [3]. The BNP level has been shown to be
increased in patients with liver cirrhosis as well [5].
Therefore, determining these conditions may reveal
stronger results in studies evaluating the effects of changes
in BNP level.
One of the important prognostic factors prior to per-
forming coronary artery bypass surgery is estimating BNP
level. However, except for cardiac diseases, elevated BNP
level may be seen in several diseases. In addition, one
should keep in mind that BNP alone without other pre-
dictive markers may not give exact information to clini-
cians about prognostic indication of the patients.
Therefore, we think that BNP level should be evaluated
along with levels of other serum mortality predictive
markers.
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